The impact of different course of insulin treatment on beta-Cell function in newly diagnosed type 2 Diabetes after short-term intensive insulin therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10001618

Enrollment

Unknown

Registered

2010-09-16

Start date

2010-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Group1:premix lispro insulin 25 for 3 months

Group 2:premix lispro insulin 25 for 6 months

Group 3:premix lispro insulin 25 for 9months

Goup 4:premix lispro insulin 25 for 12 months

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with newly diagnosed type 2 Diabetes based on WHO criteria

Exclusion criteria

Exclusion criteria: Have ever treated with oral hypoglycemic agents or insulin, positive islet autoantibody, active liver disease, renal insufficiency, cardiac insufficiency, diabetic ketonic acidosis, hyperglycemic hyperosmolar status, infection, malignancy and pregnancy.

Design outcomes

Primary

Measure	Time frame
AUCi;HOMA-beta;?I30/?G30;HOMA-IR;	—

Countries

China

Contacts

Public ContactXU Mingtong

xumingt@21cn.com+86 13719335149

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 28, 2026